New pill shows promise for nail psoriasis in first human test

NCT ID NCT05124080

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested deucravacitinib, an oral drug, for treating nail psoriasis. The goal was to see if it improves nail appearance and symptoms. Only one person took part, and researchers measured changes in nail psoriasis severity over 48 weeks. Because it's so small, the results are just a first step.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Deucravacitinib

What this could lead to

If this works, it could point toward a new oral treatment for nail psoriasis, a condition that can be hard to treat.

What could go wrong

This is a very early, tiny study with only one participant, so results are not reliable. Larger trials are needed to know if it really helps.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NAIL PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Alabama at Birmingham - Department of Dermatology

    Birmingham, Alabama, 35233, United States